Regen Biopharma restates FY2024 financials; prior statements not reliable

Regen BioPharma Inc

Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.
Derivative liability increased by $6,816; total liabilities restated to $5.38M.
Net loss restated from $809,255 to $668,255, improvement of $198,995.
Prepaid assets reduced by $16,527; total assets restated to $161,084.
Additional paid-in capital decreased by $17,492; AOCI shows negative $204,847 from reclassification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.